Biotech vet Gilman is back, heading up next-gen CAR-T startup Obsidian – FierceBiotech
|
Biotech vet Gilman is back, heading up next-gen CAR–T startup Obsidian
FierceBiotech According to Gilman, CAR–T cells exist “on a therapeutic knife edge, teetering between profound efficacy and brutal toxicity [and] they need to be tamed.” Obsidian is setting out to bring the technology into line thanks to a platform developed by its … |
